| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author index
|
|
|
|
21 |
S1 |
p. S141-S153
|
artikel
|
| 2 |
ePS6.09 A discrete choice experiment to quantify the influence of trial features on patients’ decisions to join cystic fibrosis clinical trials
|
Dobra, R.
|
|
|
21 |
S1 |
p. S60
|
artikel
|
| 3 |
ePS5.07 Alkalosis-induced hypoventilation in cystic fibrosis: the importance of efficient renal adaptation
|
Berg, P.
|
|
|
21 |
S1 |
p. S57
|
artikel
|
| 4 |
ePS4.06 Antibody response to administration of 2 doses of the BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
|
Alicandro, G.
|
|
|
21 |
S1 |
p. S53-S54
|
artikel
|
| 5 |
ePS6.10 A real-world study evaluating the impact of elexacaftor/tezacaftor/ivacaftor treatment on medication adherence in cystic fibrosis
|
Sutton, S.
|
|
|
21 |
S1 |
p. S60
|
artikel
|
| 6 |
ePS2.03 A service evaluation of ‘CF THRIVE’: an online, student-led group for children with cystic fibrosis
|
Pilbury, M.
|
|
|
21 |
S1 |
p. S46-S47
|
artikel
|
| 7 |
ePS6.02 CFTR modulators improve bicarbonate transport via the CFTR variant D1152H (c.3453G>C) in primary human intestinal epithelial cells
|
Angyal, D.
|
|
|
21 |
S1 |
p. S58
|
artikel
|
| 8 |
ePS6.01 Characterisation of F508del-CFTR rescue by corrector PTI-801
|
Lopes-Pacheco, M.
|
|
|
21 |
S1 |
p. S58
|
artikel
|
| 9 |
ePS5.04 Chronic exposure to Aspergillus fumigatus leads to cell death and increased eosinophilia in the airways of cystic fibrosis mice
|
Williams, T.J.
|
|
|
21 |
S1 |
p. S56
|
artikel
|
| 10 |
ePS2.02 Comparison of FEV on a remote spirometry device with hospital software in an adult cystic fibrosis cohort
|
Wilson, P.
|
|
|
21 |
S1 |
p. S46
|
artikel
|
| 11 |
ePS5.09 Comparison of the Lung Clearance Index in preschool children with primary ciliary dyskinesia and cystic fibrosis
|
Röhmel, J.
|
|
|
21 |
S1 |
p. S58
|
artikel
|
| 12 |
ePS4.07 COVID-19 early vaccination campaign in Italian cystic fibrosis (CF) patients: the experience of the Italian Society for the Study of Cystic Fibrosis (SIFC)
|
Lucca, F.
|
|
|
21 |
S1 |
p. S54
|
artikel
|
| 13 |
ePS4.09 COVID-19 vaccination in households of paediatric cystic fibrosis patients - experience of The Cystic Fibrosis Centre in Zagreb, Croatia
|
Bambir, I.
|
|
|
21 |
S1 |
p. S54-S55
|
artikel
|
| 14 |
ePS4.08 COVID-19 vaccine uptake in adult people with cystic fibrosis
|
Mir, M.H.
|
|
|
21 |
S1 |
p. S54
|
artikel
|
| 15 |
ePS5.01 Cystic fibrosis (CF) patients chronically infected with Pseudomonas aeruginosa have widespread alterations in both innate and adaptive immunity
|
Lausen, M.
|
|
|
21 |
S1 |
p. S55
|
artikel
|
| 16 |
ePS5.05 Cystic fibrosis chronic rhinosinusitis: implications of automated versus manual sinus computed tomography (CT) analysis and patient-reported symptoms
|
Taylor-Cousar, J.
|
|
|
21 |
S1 |
p. S56-S57
|
artikel
|
| 17 |
ePS3.02 Deciphering the adaptive evolution of successful Pseudomonas aeruginosa lineages within persistent bacterial infections
|
Espaillat, A.
|
|
|
21 |
S1 |
p. S49
|
artikel
|
| 18 |
ePS3.04 Does Achromobacter xylosoxidans have specific characteristics that could contribute to its emergence in cystic fibrosis?
|
Sorlin, P.
|
|
|
21 |
S1 |
p. S50
|
artikel
|
| 19 |
ePS5.03 Down-regulation of Aspergillus fumigatus-induced IFNβ and IFNλ1 expression in cystic fibrosis bronchial epithelial cells is partially rescued by CFTR modulator treatment
|
Laverty, S.
|
|
|
21 |
S1 |
p. S56
|
artikel
|
| 20 |
ePS1.10 Easy Medicines for Burden Reduction And Care Enhancement (EMBRACE): exploring the views of adults with cystic fibrosis on the current nebulised medicines supply process using homecare deliveries in 2 UK centres
|
Lynam, A.
|
|
|
21 |
S1 |
p. S45-S46
|
artikel
|
| 21 |
ePS5.02 Effect of omalizumab on glucocorticoid use and lung function in the treatment of allergic bronchopulmonary aspergillosis in people with cystic fibrosis: a systematic review and meta-analysis
|
Elborn, J.S.
|
|
|
21 |
S1 |
p. S55-S56
|
artikel
|
| 22 |
ePS6.05 ELX/TEZ/IVA vs. TEZ/IVA in intestinal organoids: analysis of 63 individuals with cystic fibrosis
|
Furstova, E.
|
|
|
21 |
S1 |
p. S59
|
artikel
|
| 23 |
ePS6.03 Enabling RNA-based gene modification in high-throughput screenings using cystic fibrosis patient-derived organoids
|
del Angel Zuvirie, C.
|
|
|
21 |
S1 |
p. S59
|
artikel
|
| 24 |
ePS4.04 Evaluation of burden of the COVID-19 pandemic among the cystic fibrosis community in Brno, Czech Republic
|
Mala, M.
|
|
|
21 |
S1 |
p. S53
|
artikel
|
| 25 |
ePS4.10 Evaluation of possible adverse events in relationship to the SARS-CoV-2 vaccination in cystic fibrosis patients with or without lung transplantation: a retrospective single-centre case series
|
Gautschi, F.
|
|
|
21 |
S1 |
p. S55
|
artikel
|
| 26 |
ePS1.06 Evolution of psychological distress during progression of the COVID-19 pandemic in adults with cystic fibrosis
|
Cresta, F.
|
|
|
21 |
S1 |
p. S44
|
artikel
|
| 27 |
ePS4.05 Evolving cystic fibrosis care during COVID-19: a single-centre experience
|
Spoletini, G.
|
|
|
21 |
S1 |
p. S53
|
artikel
|
| 28 |
ePS2.10 Exercise testing and training in cystic fibrosis clinics in the United Kingdom: a 10-year update
|
Tomlinson, O.W.
|
|
|
21 |
S1 |
p. S48-S49
|
artikel
|
| 29 |
ePS1.09 Exploring associations and indirect effects between mindfulness, psychological flexibility, and well-being in adults with cystic fibrosis: informing future interventions
|
Kauser, S.
|
|
|
21 |
S1 |
p. S45
|
artikel
|
| 30 |
ePS3.07 Exploring the therapeutic potential of iminosugars as antibacterial and antibiofilm agents in the treatment of cystic fibrosis lung disease infections
|
Esposito, A.
|
|
|
21 |
S1 |
p. S51
|
artikel
|
| 31 |
ePS2.09 Feasibility and acceptability of establishing virtual exercise classes for cystic fibrosis (CF) patients
|
Shiner, E.
|
|
|
21 |
S1 |
p. S48
|
artikel
|
| 32 |
ePS2.01 Home monitoring of airway clearance treatments (ACTs) in children and young people with cystic fibrosis
|
Raywood, E.
|
|
|
21 |
S1 |
p. S46
|
artikel
|
| 33 |
ePS1.01 Home spirometry and virtual visits in children with cystic fibrosis – the child’s perspective
|
Olofsson, F.
|
|
|
21 |
S1 |
p. S43
|
artikel
|
| 34 |
ePS1.05 Impact of COVID-19 on mental health among people with cystic fibrosis
|
Chrysochoou, E.-A.
|
|
|
21 |
S1 |
p. S44
|
artikel
|
| 35 |
ePS4.02 Impact of COVID-19 on the disease course in cystic fibrosis? A Registry-based study
|
Vandekerckhove, J.
|
|
|
21 |
S1 |
p. S52
|
artikel
|
| 36 |
ePS5.06 Implementing tablet-based ototoxicity screening in adults with cystic fibrosis
|
Boreland, S.
|
|
|
21 |
S1 |
p. S57
|
artikel
|
| 37 |
ePS3.05 Induced levofloxacin resistance persists in evolved lineages of Pseudomonas aeruginosa isolates from people with cystic fibrosis after exposure to other inhaled antibiotics
|
Sloan, C.M.
|
|
|
21 |
S1 |
p. S50
|
artikel
|
| 38 |
ePS3.08 Inhaled powder tobramycin (TIP): cyclical versus continuous treatment: iBEST Study
|
Alkhatib, A.
|
|
|
21 |
S1 |
p. S51
|
artikel
|
| 39 |
ePS2.07 International collaboration and development of a cystic fibrosis physiotherapy-specific telehealth toolkit
|
Morrison, L.
|
|
|
21 |
S1 |
p. S48
|
artikel
|
| 40 |
ePS3.06 Isolation and characterisation of nebulised phage for treatment of chronic Pseudomonas aeruginosa (Pa) pulmonary infections in cystic fibrosis (CF) patients
|
Kahan-Hanum, M.
|
|
|
21 |
S1 |
p. S50
|
artikel
|
| 41 |
ePS2.04 Is tele-physiotherapy as effective as home-visit-guided physiotherapy among children with cystic fibrosis?
|
Peftoulidou, P.
|
|
|
21 |
S1 |
p. S47
|
artikel
|
| 42 |
ePS2.06 “It’s good to talk” – development of a virtual international physiotherapy discussion forum
|
Stanford, G.
|
|
|
21 |
S1 |
p. S47
|
artikel
|
| 43 |
ePS1.02 Long-term psychological impact of COVID-19 on adult patients with cystic fibrosis, including transplanted patients
|
Havermans, T.
|
|
|
21 |
S1 |
p. S43
|
artikel
|
| 44 |
ePS3.09 Methicillin-sensitive Staphylococcus aureus (MSSa) with inoculum-related reduced susceptibility to cefazolin (CZ) and piperacillintazobactam (TZP) in persons with cystic fibrosis (pwCF)
|
Svishchuk, J.
|
|
|
21 |
S1 |
p. S51-S52
|
artikel
|
| 45 |
ePS3.10 Opportunistic bacterial pathogens: potential transmissions between the patients and their domestic environment
|
Dupont, C.
|
|
|
21 |
S1 |
p. S52
|
artikel
|
| 46 |
ePS4.03 Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK
|
Lau, D.
|
|
|
21 |
S1 |
p. S53
|
artikel
|
| 47 |
ePS1.07 Parental experiences of face-to-face versus virtual cystic fibrosis clinics during the COVID-19 pandemic: questionnaire study
|
Lock, K.
|
|
|
21 |
S1 |
p. S44-S45
|
artikel
|
| 48 |
ePS2.08 Patient and parent experience of a virtual physiotherapy clinic in children with cystic fibrosis - a pilot study
|
Hoel, L.
|
|
|
21 |
S1 |
p. S48
|
artikel
|
| 49 |
ePS3.01 Preliminary results of an ongoing study, which determines the prevalence and possible impact of mucoid Staphylococcus aureus on lung disease of people with cystic fibrosis
|
Rumpf, C.
|
|
|
21 |
S1 |
p. S49
|
artikel
|
| 50 |
ePS6.08 Second-hand smoke exposure reduces the clinical efficacy of ivacaftor in G551D: results from the GOAL study
|
Rowe, S.M.
|
|
|
21 |
S1 |
p. S60
|
artikel
|
| 51 |
ePS1.04 Sleep disturbances in children with cystic fibrosis at the beginning and in the first year of the COVID-19 pandemic
|
Eyuboglu, T. Sismanlar
|
|
|
21 |
S1 |
p. S44
|
artikel
|
| 52 |
ePS6.04 Specialised pro-resolving mediators’ biosynthesis by cystic fibrosis airway epithelial cells and their impact on mucociliary clearance
|
Briottet, M.
|
|
|
21 |
S1 |
p. S59
|
artikel
|
| 53 |
ePS6.07 SpliSense’s ASO SPL84-23-1 properly distributes and is retained in cystic fibrosis-like mice lungs
|
Hart, G.
|
|
|
21 |
S1 |
p. S59-S60
|
artikel
|
| 54 |
ePS1.08 Telemedicine clinics for people with cystic fibrosis (CF): experiences 18 months on
|
Mir, M.H.
|
|
|
21 |
S1 |
p. S45
|
artikel
|
| 55 |
ePS5.08 The effects on systemic inflammation of elexacaftor/tezacaftor/ivacaftor
|
Robinson, N.
|
|
|
21 |
S1 |
p. S57
|
artikel
|
| 56 |
ePS1.03 The impact of the COVID-19 lockdown and introduction of precision medication Symkevi and Orkambi on cystic fibrosis patients at Sheffield Children’s NHS Foundation Trust, UK (SCFT)
|
Braisdell, K.
|
|
|
21 |
S1 |
p. S43-S44
|
artikel
|
| 57 |
ePS4.01 The impact of the SARS-CoV-2 pandemic on people with cystic fibrosis (CF) in Ireland: did individuals maintain their key health outcomes?
|
Rees, H.
|
|
|
21 |
S1 |
p. S52
|
artikel
|
| 58 |
ePS2.05 Use of BEAM to enhance participation in exercise
|
Johnson, A.
|
|
|
21 |
S1 |
p. S47
|
artikel
|
| 59 |
ePS3.03 Using patient-derived airway models to study Pseudomonas aeruginosa colonisation and infection
|
Lolle, S.
|
|
|
21 |
S1 |
p. S49-S50
|
artikel
|
| 60 |
P130 Achromobacter spp. phenotypic differences between chronic and occasional lung infection in cystic fibrosis
|
Saitta, G.M.
|
|
|
21 |
S1 |
p. S101
|
artikel
|
| 61 |
P214 A comparison of airway clearance devices in adult cystic fibrosis patients: NIPPY Clearway2 versus Intermittent Positive Pressure Breathing (IPPB)
|
Brown, R.
|
|
|
21 |
S1 |
p. S126
|
artikel
|
| 62 |
P056 Acute pulmonary exacerbation markedly weakens beneficial effect of elexacaftor/tezacaftor/ivacaftor on systemic endothelial dysfunction in cystic fibrosis - a single case study
|
Salobir, B.
|
|
|
21 |
S1 |
p. S77
|
artikel
|
| 63 |
P233 Adherence of nebuliser use in children with cystic fibrosis
|
Lock, K.
|
|
|
21 |
S1 |
p. S132
|
artikel
|
| 64 |
P182 Adiponectin, glucose metabolism and body composition in cystic fibrosis
|
Nielsen, B.U.
|
|
|
21 |
S1 |
p. S117
|
artikel
|
| 65 |
P177 Adults with Cystic Fibrosis-Related Diabetes have a significantly elevated rate of gastrointestinal symptoms assessed with the CFAbd-Score
|
Caley, L.R.
|
|
|
21 |
S1 |
p. S115
|
artikel
|
| 66 |
P081 Adverse drug reactions linked to prolonged use of Kaftrio®
|
Dooney, M.K.
|
|
|
21 |
S1 |
p. S85
|
artikel
|
| 67 |
P078 Adverse effects of Kaftrio® in an adult cystic fibrosis clinic
|
McCabe, D.
|
|
|
21 |
S1 |
p. S84
|
artikel
|
| 68 |
P178 A feasibility assessment of delivering a glycaemic index dietary intervention for managing glucose abnormalities in people with cystic fibrosis
|
Birch, L.
|
|
|
21 |
S1 |
p. S115-S116
|
artikel
|
| 69 |
P215 Airway clearance physiotherapy and health-related quality of life in cystic fibrosis - a substudy of a series of n-of-1 randomised controlled trials
|
Gursli, S.
|
|
|
21 |
S1 |
p. S126
|
artikel
|
| 70 |
P114 Airway colonisation by filamentous fungi in patients with cystic fibrosis from a tertiary care hospital in Madrid: a 2-year prevalence study
|
del Riquelme, A. Pascual
|
|
|
21 |
S1 |
p. S96
|
artikel
|
| 71 |
P118 Airways respiratory viral infections in cystic fibrosis
|
Bianchimani, C.
|
|
|
21 |
S1 |
p. S97
|
artikel
|
| 72 |
P157 A modified rapid review of gastrointestinal symptoms in people with cystic fibrosis on cystic fibrosis transmembrane regulator modulator therapies
|
Sills, D.
|
|
|
21 |
S1 |
p. S109
|
artikel
|
| 73 |
P170 An assessment of terminal ileum morphology using magnetic resonance imaging in people with cystic fibrosis
|
Lim, G.
|
|
|
21 |
S1 |
p. S113
|
artikel
|
| 74 |
P184 An evaluation of virtual Cystic Fibrosis-Related Diabetes (CFRD) clinics in the adult service during the COVID-19 pandemic in Northern Ireland (NI)
|
Molloy, E.
|
|
|
21 |
S1 |
p. S117-S118
|
artikel
|
| 75 |
P062 An international survey: understanding the health and perspectives of people with cystic fibrosis (CF) not benefitting from CFTR modulators
|
Kramer-Golkinkoff, E.
|
|
|
21 |
S1 |
p. S79
|
artikel
|
| 76 |
P053 A novel family-focused intervention to support physical activity among children (6–12 years) with cystic fibrosis
|
Tomlinson, O.W.
|
|
|
21 |
S1 |
p. S76
|
artikel
|
| 77 |
P021 A novel gene delivery approach for CRISPR-Cas9-mediated permanent CFTR correction
|
Hu, J.
|
|
|
21 |
S1 |
p. S66
|
artikel
|
| 78 |
P033 Anti-inflammatory effects of Kaftrio® in adults with cystic fibrosis heterozygous for F508del-CFTR
|
Jarosz-Griffiths, H.
|
|
|
21 |
S1 |
p. S69-S70
|
artikel
|
| 79 |
P150 Antimicrobial prescribing in people with cystic fibrosis: exploring inhaled antibiotic use for Pseudomonas aeruginosa infections across the ECFS-CTN
|
Sloan, C.M.
|
|
|
21 |
S1 |
p. S107
|
artikel
|
| 80 |
P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation
|
Oren, Y.S.
|
|
|
21 |
S1 |
p. S68
|
artikel
|
| 81 |
P028 Antisense oligonucleotide splicing modulation as a novel cystic fibrosis (CF) therapeutic approach for the W1282X nonsense mutation
|
Barchad, O. Avizur
|
|
|
21 |
S1 |
p. S68
|
artikel
|
| 82 |
P206 A questionnaire to gain an understanding of adherence to inhaled therapies, airway clearance and exercise since commencing the triple combination modulator in cystic fibrosis
|
Reid, C.
|
|
|
21 |
S1 |
p. S123-S124
|
artikel
|
| 83 |
P208 A retrospective observational study of the effects of Kaftrio® on the current cohort of patients at Nottingham University Hospitals NUH trust
|
Hardiman, K.
|
|
|
21 |
S1 |
p. S124
|
artikel
|
| 84 |
P252 A service improvement project: identifying and addressing problems experienced by adults with cystic fibrosis relating to the supply of medicines in primary care
|
Chawla, M.
|
|
|
21 |
S1 |
p. S137
|
artikel
|
| 85 |
P025 Assessment of CFTR modulator combinations in rectal organoids from F508del homozygous patients with cystic fibrosis
|
Cuyx, S.
|
|
|
21 |
S1 |
p. S67
|
artikel
|
| 86 |
P189 Assessment of total dietary salt intake: highlighting the need for regular detailed dietetic analysis of total salt intake in a Liverpool, UK paediatric cystic fibrosis centre
|
Berry, C.A.
|
|
|
21 |
S1 |
p. S119
|
artikel
|
| 87 |
P220 Assessment of use of Manchester musculoskeletal screening tool in cystic fibrosis adults
|
Hodgson, N.
|
|
|
21 |
S1 |
p. S128
|
artikel
|
| 88 |
P210 Association of anaerobic threshold variables from cardiopulmonary exercise testing with the risk for exacerbation in patients with cystic fibrosis
|
Campos, N. Evangelista
|
|
|
21 |
S1 |
p. S125
|
artikel
|
| 89 |
P059 Association of Pseudomonas aeruginosa infection stage with lung function trajectory in children with cystic fibrosis
|
Rosenfeld, M.
|
|
|
21 |
S1 |
p. S78
|
artikel
|
| 90 |
P111 Atopy and cystic fibrosis: characterisation of a paediatric Portuguese population
|
Castanhinha, S.
|
|
|
21 |
S1 |
p. S95
|
artikel
|
| 91 |
P249 Awareness of the potential benefits of occupational therapy in a cystic fibrosis multidisciplinary team
|
Mitchell, J.E.
|
|
|
21 |
S1 |
p. S136
|
artikel
|
| 92 |
P223 Bare Bones - a re-audit of bone health management in patients with cystic fibrosis at St. Vincent’s University Hospital
|
Kelly, S.
|
|
|
21 |
S1 |
p. S129
|
artikel
|
| 93 |
P100 Beneficial effects and safety of omalizumab during pregnancy in a patient with cystic fibrosis
|
Riberi, L.
|
|
|
21 |
S1 |
p. S91
|
artikel
|
| 94 |
P138 Biochemical detection of Pseudomonas aeruginosa in sputum and urine from children with cystic fibrosis
|
Sandvik, R. Mulvad
|
|
|
21 |
S1 |
p. S103
|
artikel
|
| 95 |
P162 Body composition assessment in cystic fibrosis (CF) patients on elexacaftor/texacaftor/ivacaftor
|
Zamponi, V.
|
|
|
21 |
S1 |
p. S110-S111
|
artikel
|
| 96 |
P161 Body mass index change in adult patients with cystic fibrosis following the introduction of triple CFTR therapy elexacaftor/tezacaftor/ivacaftor: a regional adult cystic fibrosis centre experience
|
Barrett, J.
|
|
|
21 |
S1 |
p. S110
|
artikel
|
| 97 |
P199 Bone health and associated factors at an adult cystic fibrosis unit
|
Mitchell-Whyte, M.
|
|
|
21 |
S1 |
p. S121-S122
|
artikel
|
| 98 |
P198 Bone health monitoring and treatment at an adult cystic fibrosis centre
|
Mitchell-Whyte, M.
|
|
|
21 |
S1 |
p. S121
|
artikel
|
| 99 |
P197 Bone health status over time in people with cystic fibrosis and adherence to assessment of bone health guidelines at University Hospital Limerick
|
Tierney, A.
|
|
|
21 |
S1 |
p. S121
|
artikel
|
| 100 |
P201 Bowel screening for cancer in pre-transplant people with cystic fibrosis and the accuracy of faecal immunochemical testing
|
Lillis, A.
|
|
|
21 |
S1 |
p. S122
|
artikel
|
| 101 |
P143 Bronchopulmonary infection/colonisation in Spanish cystic fibrosis patients: preliminary results of a multicentre study
|
Maruri-Aransolo, A.
|
|
|
21 |
S1 |
p. S104-S105
|
artikel
|
| 102 |
P218 Calibration and cross-validation of accelerometry in children and adolescents with cystic fibrosis
|
Bianchim, M.S.
|
|
|
21 |
S1 |
p. S127
|
artikel
|
| 103 |
P065 Cervical cancer screening in women with cystic fibrosis (CF): should we do more?
|
Hadfield, M.
|
|
|
21 |
S1 |
p. S80
|
artikel
|
| 104 |
P227 “CF Hero” application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis
|
Jirásek, M.
|
|
|
21 |
S1 |
p. S130
|
artikel
|
| 105 |
P007 CFTR genotypes and spermatology in cystic fibrosis patients without CBAVD
|
Sedova, A.
|
|
|
21 |
S1 |
p. S63
|
artikel
|
| 106 |
P202 CFTR modulation may help refine transplant decisions in lung-liver transplant candidates
|
Germanova, D.
|
|
|
21 |
S1 |
p. S122-S123
|
artikel
|
| 107 |
P119 CFTR modulators therapy and lung microbiota diversity in adult cystic fibrosis patients
|
Voronina, O.
|
|
|
21 |
S1 |
p. S98
|
artikel
|
| 108 |
P256 Change in the anxiety levels of children with cystic fibrosis and their mothers at the beginning of the COVID-19 pandemic and after 1 year
|
Asfuroglu, P.
|
|
|
21 |
S1 |
p. S138-S139
|
artikel
|
| 109 |
P039 Changes to clinical well-being following initiation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis – single-centre experience
|
McGrath, A.
|
|
|
21 |
S1 |
p. S71
|
artikel
|
| 110 |
P066 Changing criteria of paediatric chronic rhinosinusitis indexation in the Russian National Cystic Fibrosis Registry
|
Polyakov, D.
|
|
|
21 |
S1 |
p. S80
|
artikel
|
| 111 |
P068 Characteristics of genetic variants of the CFTR gene in the Russian Federation according to the 2020 Registry
|
Voronkova, A.
|
|
|
21 |
S1 |
p. S81
|
artikel
|
| 112 |
P041 Clinical assessment plan for initiation and follow-up of treatment with elexacaftor/tezacaftor/ivacaftor in the Danish cystic fibrosis population
|
Leo-Hansen, C.
|
|
|
21 |
S1 |
p. S72
|
artikel
|
| 113 |
P131 Clinical impact of Aspergillus fumigatus in children with cystic fibrosis
|
Fainardi, V.
|
|
|
21 |
S1 |
p. S101
|
artikel
|
| 114 |
P180 Clinical practice versus guidelines for the screening of Cystic Fibrosis-Related Diabetes (CFRD): a French survey of 47 centres
|
Weiss, L.
|
|
|
21 |
S1 |
p. S116
|
artikel
|
| 115 |
P234 CoachMois: the experience of an adapted physical activity challenge online at the Roscoff Cystic Fibrosis Centre (Brittany, FR)
|
Dubois, A.
|
|
|
21 |
S1 |
p. S132
|
artikel
|
| 116 |
P107 Coexistence of cystic fibrosis and metabolic disease: is this a related or coincidental condition?
|
Buyuksahin, H. Nayır
|
|
|
21 |
S1 |
p. S94
|
artikel
|
| 117 |
P139 Colistin-rifampicin combination is efficient against biofilms of colistin-resistant Pseudomonas aeruginosa from cystic fibrosis patients
|
Ciofu, O.
|
|
|
21 |
S1 |
p. S103-S104
|
artikel
|
| 118 |
P124 Collateral sensitivity in multidrug-resistant Pseudomonas aeruginosa
|
Kolpen, M.
|
|
|
21 |
S1 |
p. S99
|
artikel
|
| 119 |
P236 Commit to Fit – access to gym space for young people with cystic fibrosis in partnership with Helping Hand charity
|
Baby, N.
|
|
|
21 |
S1 |
p. S132-S133
|
artikel
|
| 120 |
P136 Comparative characteristics of patients with nontuberculous mycobacteria in the Russian Federation according to the 2020 Registry
|
Kondratueva, E.
|
|
|
21 |
S1 |
p. S102-S103
|
artikel
|
| 121 |
P135 Comparative characteristics of patients with nontuberculous mycobacteria (NTM) in the Russian Federation according to the 2020 Registry
|
Kondratyeva, E.
|
|
|
21 |
S1 |
p. S102
|
artikel
|
| 122 |
P090 Comparison of Multiple Breath Washout and particles in exhaled air for assessment of small airway function in children with cystic fibrosis (CF)
|
Zwitserloot, A.M.
|
|
|
21 |
S1 |
p. S88
|
artikel
|
| 123 |
P115 Comparison of total bacterial and Pseudomonas aeruginosa load during PEx between infrequent and frequent exacerbators
|
Houston, C.J.
|
|
|
21 |
S1 |
p. S96
|
artikel
|
| 124 |
P048 Continuous glucose monitoring in people with cystic fibrosis highlights different glucose tolerance abnormalities according to pancreatic exocrine status.
|
Rakotoarisoa, L.
|
|
|
21 |
S1 |
p. S74
|
artikel
|
| 125 |
P091 Correlation of lung function using forced oscillation technique with spirometry in children aged 4–18 years with cystic fibrosis (CF)
|
Singh, S.
|
|
|
21 |
S1 |
p. S88
|
artikel
|
| 126 |
P154 Cough swabs are not a suitable alternative to a sputum culture for fungal culture to isolate Aspergillus fumigatus
|
Francis, N.
|
|
|
21 |
S1 |
p. S108
|
artikel
|
| 127 |
P084 Counteracting inflammation triggered by Pseudomonas aeruginosa-ctivated lung-infiltrating Th1/17 cells: a novel approach for precision medicine in cystic fibrosis
|
Paroni, M.
|
|
|
21 |
S1 |
p. S86
|
artikel
|
| 128 |
P076 COVID-19 vaccination in children and adolescents with cystic fibrosis - a single-centre experience
|
Zver, A.
|
|
|
21 |
S1 |
p. S83-S84
|
artikel
|
| 129 |
P075 COVID-19 vaccination uptake in patients with cystic fibrosis
|
Manning, D.-E.
|
|
|
21 |
S1 |
p. S83
|
artikel
|
| 130 |
P087 CTN – Lung Clearance Index core facility: quality improvement exercise
|
Saunders, C.
|
|
|
21 |
S1 |
p. S86-S87
|
artikel
|
| 131 |
P001 Cystic fibrosis newborn screening (CF-NBS) start-up in Flanders (Belgium): report of first evaluation after 3 years
|
Proesmans, M.
|
|
|
21 |
S1 |
p. S61
|
artikel
|
| 132 |
P203 Cystic fibrosis-related diseases at the Centre for Cystic Fibrosis, Institute for Respiratory Diseases in Children in Skopje, Republic of North Macedonia
|
Momchilovikj, S.
|
|
|
21 |
S1 |
p. S123
|
artikel
|
| 133 |
P083 Decreased respiratory burst in circulating neutrophils after initiation of CFTR modulator therapy in cystic fibrosis patients with chronic lung infections
|
Jensen, P.Ø.
|
|
|
21 |
S1 |
p. S85-S86
|
artikel
|
| 134 |
P196 Detecting bone disease in patients with cystic fibrosis: influence of genetic and clinical factors over reduced bone mass
|
Maretti, T. Jakovska
|
|
|
21 |
S1 |
p. S121
|
artikel
|
| 135 |
P250 Development of a new informational resource on fasting during Ramadan and cystic fibrosis
|
Carter, J.
|
|
|
21 |
S1 |
p. S136-S137
|
artikel
|
| 136 |
P151 Drug sensitivity of Mycobacterium abscessus in patients with cystic fibrosis
|
Kondratyeva, E.
|
|
|
21 |
S1 |
p. S107
|
artikel
|
| 137 |
P247 Dutch translation of the gastrointestinal (GI) symptom tracker for people with cystic fibrosis (CF)
|
Verkleij, M.
|
|
|
21 |
S1 |
p. S136
|
artikel
|
| 138 |
P192 Early adrenal activation in boys with cystic fibrosis may explain impaired final height
|
Tamer, G.
|
|
|
21 |
S1 |
p. S120
|
artikel
|
| 139 |
P030 Effect of CFTR modulators on lung function, body mass index, and Pseudomonas aeruginosa status in adolescents with cystic fibrosis - one-year follow-up
|
Praprotnik, M.
|
|
|
21 |
S1 |
p. S68-S69
|
artikel
|
| 140 |
P095 Effect of hypertonic saline therapy on Lung Clearance Index in preschool children with cystic fibrosis
|
Ergenekon, A.P.
|
|
|
21 |
S1 |
p. S89
|
artikel
|
| 141 |
P027 Effects of ivacaftor therapy confirm the results of theratyping using rectal and nasal epithelial cells of a cystic fibrosis patient carrying the ultra-rare CFTR genotype W57G (c.169T > G)/A234D (c.701C > A)
|
Conti, J.
|
|
|
21 |
S1 |
p. S67-S68
|
artikel
|
| 142 |
P174 Effects of proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: a matched cohort study
|
Sciarrabba, C.S.
|
|
|
21 |
S1 |
p. S114-S115
|
artikel
|
| 143 |
P116 Effects of SymkeviTM(tezacaftor/ivacaftor) on the lung and gut microbiota in cystic fibrosis
|
Marsh, R.
|
|
|
21 |
S1 |
p. S97
|
artikel
|
| 144 |
P035 Elexacaftor/tezacaftor/ivacaftor improves FEV1 and 6MWT very quickly in patients with cystic fibrosis (CF) and severe airflow obstruction
|
Mely, L.
|
|
|
21 |
S1 |
p. S70
|
artikel
|
| 145 |
P204 Elexacaftor/tezacaftor/ivacaftor - positive effects on quality of life using the AWESCORE and exercise capacity using the A-STEP in adults with end-stage cystic fibrosis
|
Button, B.
|
|
|
21 |
S1 |
p. S123
|
artikel
|
| 146 |
P240 Elexacaftor/tezacaftor/ivacaftor treatment improves cystic fibrosis quality of life over multiple domains
|
Robinson, N.
|
|
|
21 |
S1 |
p. S134
|
artikel
|
| 147 |
P038 ELX/TEZ/IVA discontinuation is more common in an older population
|
Sapru, K.
|
|
|
21 |
S1 |
p. S71
|
artikel
|
| 148 |
P128 Epidemiological significance of Achromobacter spp. chronic lung infection in patients with cystic fibrosis
|
Chernukha, M.
|
|
|
21 |
S1 |
p. S100
|
artikel
|
| 149 |
P140 Eradication treatment of Pseudomonas aeruginosa infections in children with cystic fibrosis
|
Gulieva, A.
|
|
|
21 |
S1 |
p. S104
|
artikel
|
| 150 |
P219 Establishing a review process for patients using non-invasive ventilation for airway clearance in the St. Bartholomew’s cystic fibrosis adult population
|
Goodwin, G.
|
|
|
21 |
S1 |
p. S127-S128
|
artikel
|
| 151 |
P194 Evaluation of bone mineral density indicators in children with cystic fibrosis: dynamics of indicators over 15 years
|
Zhekaite, E.
|
|
|
21 |
S1 |
p. S120-S121
|
artikel
|
| 152 |
P109 Evaluation of early lung disease in school-age children with cystic fibrosis - a preliminary report
|
Walicka-Serzysko, K.
|
|
|
21 |
S1 |
p. S94-S95
|
artikel
|
| 153 |
P085 Evaluation of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and mean platelet volume in cystic fibrosis (CF) during exacerbation
|
Asfuroglu, P.
|
|
|
21 |
S1 |
p. S86
|
artikel
|
| 154 |
P103 Evaluation of patient opinion about the current and future pharmacy service for an adult cystic fibrosis clinic
|
McCabe, D.
|
|
|
21 |
S1 |
p. S92
|
artikel
|
| 155 |
P004 Evaluation of the efficacy of newborn screening as a tool to identify cystic fibrosis in the Russian Federation
|
Sherman, V.
|
|
|
21 |
S1 |
p. S62
|
artikel
|
| 156 |
P097 Evaluation of the inhaled mannitol tolerance test in children with cystic fibrosis
|
Shadrina, V.
|
|
|
21 |
S1 |
p. S90
|
artikel
|
| 157 |
P020 Evaluation of TMEM16A as a modifier of the cystic fibrosis lung phenotype utilising cystic fibrosis patient-specific human-induced pluripotent stem cells
|
Jaboreck, M.-C.
|
|
|
21 |
S1 |
p. S65-S66
|
artikel
|
| 158 |
P129 Evidence for a role of Achromobacter xylosoxidans VBNC forms in chronic cystic fibrosis lung infection
|
Cirilli, N.
|
|
|
21 |
S1 |
p. S100
|
artikel
|
| 159 |
P224 Evolution of dry powder inhaled colistimethate sodium (Colobreathe®) in a large adult cystic fibrosis centre
|
Yarwood, V.
|
|
|
21 |
S1 |
p. S129
|
artikel
|
| 160 |
P217 Exercise as airway clearance therapy (ExACT) in cystic fibrosis: a UK-based e-Delphi survey of patients, caregivers and health professionals
|
Saynor, Z.
|
|
|
21 |
S1 |
p. S127
|
artikel
|
| 161 |
P237 Exercise immunology and cystic fibrosis
|
Hugues, G.
|
|
|
21 |
S1 |
p. S133
|
artikel
|
| 162 |
P036 Exercise performance before and after introduction of elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in Scottish children with cystic fibrosis: a 2-centre retrospective study
|
Burns, P.D.
|
|
|
21 |
S1 |
p. S70-S71
|
artikel
|
| 163 |
P092 Exploring the association between hand grip strength (HGS) and lung function (FEV1%) in cystic fibrosis: does HGS offer an insight into pulmonary function?
|
Taylor, M.
|
|
|
21 |
S1 |
p. S88-S89
|
artikel
|
| 164 |
P104 Exploring the value of annual chest radiographs in people with cystic fibrosis: an observational study from a single UK centre
|
Stovin, C.
|
|
|
21 |
S1 |
p. S92-S93
|
artikel
|
| 165 |
P165 Exploring weight change and subjective experiences on Kaftrio® in adults with cystic fibrosis
|
Sheibani, L.
|
|
|
21 |
S1 |
p. S112
|
artikel
|
| 166 |
P060 Factors associated with pulmonary functions of cystic fibrosis (CF) patients in the National Cystic Fibrosis Patient Registry: a retrospective cohort study
|
Çobanogĝlu, N.
|
|
|
21 |
S1 |
p. S78-S79
|
artikel
|
| 167 |
P238 Family participation in cystic fibrosis care
|
Houben, J.
|
|
|
21 |
S1 |
p. S133
|
artikel
|
| 168 |
P232 Feasibility and added value of the computer game “Sparky©” when learning spirometry in preschool children with cystic fibrosis
|
Vreys, M.
|
|
|
21 |
S1 |
p. S131-S132
|
artikel
|
| 169 |
P190 Features of dosing of enzyme replacement therapy in children with cystic fibrosis in the Russian Federation: cross-sectional study
|
Maksimycheva, T.
|
|
|
21 |
S1 |
p. S119
|
artikel
|
| 170 |
P005 Five-year performance analysis of a cystic fibrosis newborn screening program in northeastern Brazil
|
Almeida, C.
|
|
|
21 |
S1 |
p. S62
|
artikel
|
| 171 |
P117 Fungal colonisation in patients with cystic fibrosis: preliminary results from a national multicentre study
|
Maruri-Aransolo, A.
|
|
|
21 |
S1 |
p. S97
|
artikel
|
| 172 |
P168 Gastrointestinal (GI) symptoms and their impact on quality of life in cystic fibrosis (CF) patients
|
Danevska, I. Arnaudova
|
|
|
21 |
S1 |
p. S113
|
artikel
|
| 173 |
P010 Genotype features in patients with cystic fibrosis in the North Caucasus Federal District of the Russian Federation
|
Enina, E.
|
|
|
21 |
S1 |
p. S63-S64
|
artikel
|
| 174 |
P125 Genotype-phenotype correlation of triazole-resistant pulmonary aspergillosis in chronic respiratory disease patients
|
Aljohani, R.
|
|
|
21 |
S1 |
p. S99
|
artikel
|
| 175 |
P179 Glycaemic index dietary intervention in cystic fibrosis: preliminary findings from a feasibility study of dietary manipulation
|
Birch, L.
|
|
|
21 |
S1 |
p. S116
|
artikel
|
| 176 |
P002: Growth, lung microbiology and structure after implementation of newborn screening in Danish cystic fibrosis patients
|
Skov, M.
|
|
|
21 |
S1 |
p. S61
|
artikel
|
| 177 |
P127 Haemophilus influenza and antimicrobial resistance in children and young people with cystic fibrosis
|
Edwards, C.
|
|
|
21 |
S1 |
p. S100
|
artikel
|
| 178 |
P070 Harnessing electronic health records to enhance cbservational research in cystic fibrosis
|
Filipow, N.
|
|
|
21 |
S1 |
p. S82
|
artikel
|
| 179 |
P022 hCFTRΔR expression and correction of human cystic fibrosis airway epithelia increase with increasing SP-101 and doxorubicin doses
|
Lin, S.
|
|
|
21 |
S1 |
p. S66
|
artikel
|
| 180 |
P023 High-resolution imaging reveals impaired lung development in a mouse model of cystic fibrosis-like lung disease
|
Anagnostopoulou, P.
|
|
|
21 |
S1 |
p. S66
|
artikel
|
| 181 |
P186 High vitamin A in children under 5 years of age
|
Cahill, Ó.
|
|
|
21 |
S1 |
p. S118
|
artikel
|
| 182 |
P105 Home spirometry is reliable and of consistent quality in children with cystic fibrosis
|
O’Toole, C.F.
|
|
|
21 |
S1 |
p. S93
|
artikel
|
| 183 |
P175 How accurate is the glucose management indicator calculated by continuous glucose monitoring compared to the blood HbA1c reading in patients with cystic fibrosis?
|
Manning, D.-E.
|
|
|
21 |
S1 |
p. S115
|
artikel
|
| 184 |
P153 Hypersensitivity reactions to antibiotics in patients with cystic fibrosis
|
Kowalik, A.
|
|
|
21 |
S1 |
p. S108
|
artikel
|
| 185 |
P122 Identification and characterisation of a Liverpool Epidemic Strain (LES) isolate of Pseudomonas aeruginosa, first collected in 1986 in Calgary, Canada
|
Izydorczyk, C.
|
|
|
21 |
S1 |
p. S98
|
artikel
|
| 186 |
P108 Impact of improved nontuberculous mycobacterial culture surveillance strategy in an adult cystic fibrosis cohort
|
De Crem, N.
|
|
|
21 |
S1 |
p. S94
|
artikel
|
| 187 |
P031 Impact of the elexacaftor/tezacaftor/ivacaftor combination regimen on lung function in adults with cystic fibrosis: more than just FEV1
|
Wollsching-Strobel, M.
|
|
|
21 |
S1 |
p. S69
|
artikel
|
| 188 |
P144 Impact of the sex steroid hormone estradiol on biofilm formation and phenotype of Pseudomonas aeruginosa isolates from cystic fibrosis patients
|
Al-Zawity, J.
|
|
|
21 |
S1 |
p. S105
|
artikel
|
| 189 |
P040 Implementation and preliminary experiences of the HERO-2 real-world research study in patients with cystic fibrosis
|
Do, L.
|
|
|
21 |
S1 |
p. S72
|
artikel
|
| 190 |
P037 Improved aerobic fitness in children on CFTRm triple combination therapy
|
Krivec, U.
|
|
|
21 |
S1 |
p. S71
|
artikel
|
| 191 |
P171 Improved diagnosis and treatment of distal intestinal obstruction syndrome (DIOS) with a simplified treatment routine
|
Gilljam, M.
|
|
|
21 |
S1 |
p. S114
|
artikel
|
| 192 |
P051 Improved opportunities for trial participation via the Dutch CF Trial Consortium
|
Paalvast, I.
|
|
|
21 |
S1 |
p. S75
|
artikel
|
| 193 |
P246 Improving assessment of palliative care needs among cystic fibrosis children: a Delphi study of the ADAPT-Cystic Fibrosis communication guide
|
Middour-Oxler, B.
|
|
|
21 |
S1 |
p. S135
|
artikel
|
| 194 |
P173 Increased prevalence of celiac disease in patients with cystic fibrosis: a systematic review and meta analysis
|
Imrei, M.
|
|
|
21 |
S1 |
p. S114
|
artikel
|
| 195 |
P185 Influence of breastfeeding on the nutritional and health status of children with cystic fibrosis
|
Roslavtseva, E.
|
|
|
21 |
S1 |
p. S118
|
artikel
|
| 196 |
P183 Informative value of fructosamine in diagnosis of carbohydrate metabolism disorders in children with cystic fibrosis
|
Lyabina, N.
|
|
|
21 |
S1 |
p. S117
|
artikel
|
| 197 |
P099 Inhaled tobramycin solution hypersensitivity in patients with cystic fibrosis at the Centre for Cystic Fibrosis, Institute for Pulmonary Diseases in Children in North Macedonia
|
Nadzinska, M. Atanasova
|
|
|
21 |
S1 |
p. S91
|
artikel
|
| 198 |
P141 Interaction between bacteria in the cystic fibrosis airways
|
Gibson, E.E.
|
|
|
21 |
S1 |
p. S104
|
artikel
|
| 199 |
P052 Introduction of an innovative “pill-swallowing school” in a cystic fibrosis paediatric population within a tertiary centre
|
Rowley, R.
|
|
|
21 |
S1 |
p. S75-S76
|
artikel
|
| 200 |
P147 In vitro sensitivity of Gram-negative cystic fibrosis isolates to a 4th generation fluoroquinolone
|
Farrell, P.
|
|
|
21 |
S1 |
p. S106
|
artikel
|
| 201 |
P064 Iron deficiency in cystic fibrosis: a prospective study in a modern adult cohort
|
Lobbes, H.
|
|
|
21 |
S1 |
p. S79-S80
|
artikel
|
| 202 |
P245 Kaftrio® Impact and Side-effect Survey (KISS)
|
Holden, A.
|
|
|
21 |
S1 |
p. S135
|
artikel
|
| 203 |
P205 Kaftrio® improves VO2max in patients with cystic fibrosis
|
Kent, T.
|
|
|
21 |
S1 |
p. S123
|
artikel
|
| 204 |
P008 L138ins is a common CFTR gene mutation in infertile Russian men
|
Marnat, E.
|
|
|
21 |
S1 |
p. S63
|
artikel
|
| 205 |
P034 Long-term elexacaftor/tezacaftor/ivacaftor CFTR modulation significantly increases lung function and peak power output in people with cystic fibrosis
|
Hillen, B.
|
|
|
21 |
S1 |
p. S70
|
artikel
|
| 206 |
P225 Long-term tolerability and use of tobipodhaler in people with cystic fibrosis
|
Beverley, Z.
|
|
|
21 |
S1 |
p. S129
|
artikel
|
| 207 |
P061 Low FEV1 performance in the 30–34 years of age cohort in Norway: utilising Registry data in the search for causes
|
Os, A.
|
|
|
21 |
S1 |
p. S79
|
artikel
|
| 208 |
P120 Metaproteomics profiling of the respiratory microbiota of cystic fibrosis (CF) patients infected by Mycobacterium abscessus
|
Hardouin, P.
|
|
|
21 |
S1 |
p. S98
|
artikel
|
| 209 |
P146 Microbiological diagnostic procedures for respiratory cystic fibrosis samples: results of a survey in Italian laboratories
|
Dolce, D.
|
|
|
21 |
S1 |
p. S105-S106
|
artikel
|
| 210 |
P132 Microbiological monitoring of chronic lung infection with Achromobacter spp. in cystic fibrosis patients
|
Avetisyan, L.
|
|
|
21 |
S1 |
p. S101
|
artikel
|
| 211 |
P101 Microbiological surveillance in cystic fibrosis – an emerging multifactorial challenge
|
Barry, P.J.
|
|
|
21 |
S1 |
p. S91-S92
|
artikel
|
| 212 |
P113 Microbiology assessment in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor
|
Cirilli, N.
|
|
|
21 |
S1 |
p. S96
|
artikel
|
| 213 |
P159 Modifications of anthropometric parameters and body composition after Kaftrio® in a group of adolescents and young adults
|
Rigon, S.
|
|
|
21 |
S1 |
p. S109-S110
|
artikel
|
| 214 |
P057 Monitoring individualised CFTR modulating therapy in an adolescent with cystic fibrosis homozygous for the G85E CFTR variant using in vitro and in vivo methods
|
Ziegahn, N.
|
|
|
21 |
S1 |
p. S77
|
artikel
|
| 215 |
P145 Monitoring of pulmonary infections in the Danish cystic fibrosis cohort during CFTR modulator therapy implementation
|
Jeppesen, M.
|
|
|
21 |
S1 |
p. S105
|
artikel
|
| 216 |
P019 Monocyte integrin activation as a CFTR-targeted drugs evaluation test in cystic fibrosis patients: preliminary analysis
|
Melotti, P.
|
|
|
21 |
S1 |
p. S65
|
artikel
|
| 217 |
P006 Nephrolithiasis and nephrocalcinosis in infants with cystic fibrosis: a case presentation of 2 Swedish infants
|
Christiansen, E.
|
|
|
21 |
S1 |
p. S62
|
artikel
|
| 218 |
P164 Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis: cross-sectional analysis and effect of elexacaftor/tezacaftor/ivacaftor
|
Francalanci, M.
|
|
|
21 |
S1 |
p. S111-S112
|
artikel
|
| 219 |
P187 Nutritional status and its relation with lung function and vitamin D3 level in cystic fibrosis patients
|
Danevska, I. Arnaudova
|
|
|
21 |
S1 |
p. S118-S119
|
artikel
|
| 220 |
P073 Observed impact on admissions during the COVID-19 pandemic of paediatric cystic fibrosis patients in a tertiary hospital setting
|
Warraich, S.
|
|
|
21 |
S1 |
p. S83
|
artikel
|
| 221 |
P241 One month with elexacaftor/tezacaftor/ivacaftor in an Italian sample: quality of life and mental health
|
Graziano, S.
|
|
|
21 |
S1 |
p. S134
|
artikel
|
| 222 |
P226 Our evolving prescribing practice: inhaled medication prescription changes over 5 years at the West Midlands Adult Cystic Fibrosis Centre
|
Brown, C.
|
|
|
21 |
S1 |
p. S129-S130
|
artikel
|
| 223 |
P167 Pancreatic enzyme replacement therapy intake and gastrointestinal symptoms in adults with cystic fibrosis: a cross-sectional study in Copenhagen, Denmark
|
Olsen, M.F.
|
|
|
21 |
S1 |
p. S112-S113
|
artikel
|
| 224 |
P148 Parental perspectives on sending respiratory tract specimens for microbiology from home in children with cystic fibrosis - experience from a tertiary service provider in the northwest United Kingdom
|
Maitra, A.
|
|
|
21 |
S1 |
p. S106
|
artikel
|
| 225 |
P248 Parental reports of the oral health-related quality of life and associated factors in children with cystic fibrosis (CF)
|
Sisman, H. Ilgin
|
|
|
21 |
S1 |
p. S136
|
artikel
|
| 226 |
P024 Patient-derived organoids as a model for treatment diagnosis in cystic fibrosis – combinatory treatment with read-through agent, correctors and potentiator on rare mutations
|
Frias, J.
|
|
|
21 |
S1 |
p. S67
|
artikel
|
| 227 |
P069 Patient-reported outcome measures in children with cystic fibrosis
|
Ruseckaite, R.
|
|
|
21 |
S1 |
p. S81-S82
|
artikel
|
| 228 |
P156 Patterns of liver dysfunction and the development of a pathway for liver monitoring in adults with cystic fibrosis (CF) on elexacaftor/tezacaftor/ivacaftor (ETI): a quality improvement project
|
Sun, J.
|
|
|
21 |
S1 |
p. S109
|
artikel
|
| 229 |
P155 Paws for thought: sniffer dogs for infection surveillance in non-sputum-producing people with cystic fibrosis
|
King, J.
|
|
|
21 |
S1 |
p. S108
|
artikel
|
| 230 |
P018 People with cystic fibrosis do not show an increased interferonresponse transcriptomic signature in nasal epithelial cells
|
Jain, M.
|
|
|
21 |
S1 |
p. S65
|
artikel
|
| 231 |
P013 Peptide modulation of COMMD1: corrector and anti-inflammatory effect in cystic fibrosis context?
|
Simonneau, B.
|
|
|
21 |
S1 |
p. S64
|
artikel
|
| 232 |
P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?
|
Dillenhöfer, S.
|
|
|
21 |
S1 |
p. S124-S125
|
artikel
|
| 233 |
P063 Physiotherapy data for the UK cystic fibrosis Registry - review and re-launch
|
Morrison, L.
|
|
|
21 |
S1 |
p. S79
|
artikel
|
| 234 |
P074 Post-COVID-19 condition in children with cystic fibrosis
|
Chernyavskaya, A.
|
|
|
21 |
S1 |
p. S83
|
artikel
|
| 235 |
P133 Prevalence and factors associated with isolation of Aspergillus from sputum in patients with cystic fibrosis (CF)
|
Gjinovska-Tasevska, E.
|
|
|
21 |
S1 |
p. S101-S102
|
artikel
|
| 236 |
P134 Prevalence of multi-drug, antimicrobial-resistant bacteria in children with cystic fibrosis
|
Fainardi, V.
|
|
|
21 |
S1 |
p. S102
|
artikel
|
| 237 |
P102 Prevalence of sensitisation to common inhaled allergens in a Belgian adult cystic fibrosis population and its impact on respiratory outcomes
|
Marissiaux, H.
|
|
|
21 |
S1 |
p. S92
|
artikel
|
| 238 |
P014 Proof of concept of ionocytes’ CFTR content as a novel biomarker for cystic fibrosis diagnosis and follow-up
|
Ciciriello, F.
|
|
|
21 |
S1 |
p. S64
|
artikel
|
| 239 |
P126 Pseudomonas aeruginosa infection during long-term suppression treatment with tobramycin inhalation powder (TIP)
|
McCleave, R.
|
|
|
21 |
S1 |
p. S99-S100
|
artikel
|
| 240 |
P169 Psychometric properties of the gastrointestinal symptom tracker self-report measure
|
Graziano, S.
|
|
|
21 |
S1 |
p. S113
|
artikel
|
| 241 |
P243 Psychosocial impact of 6 months of treatment with Symkevi® among adult cystic fibrosis patients
|
Braun, S.
|
|
|
21 |
S1 |
p. S134-S135
|
artikel
|
| 242 |
P049 Question cystic fibrosis again: a refresh of the James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF)
|
Rowbotham, N.J.
|
|
|
21 |
S1 |
p. S74-S75
|
artikel
|
| 243 |
P094 Randomised controlled trial of humanoid robot-based distraction for invasive nursing procedures in children with cystic fibrosis: preliminary results
|
Bella, S.
|
|
|
21 |
S1 |
p. S89
|
artikel
|
| 244 |
P079 Real-life data on the efficacy and safety of tezacaftor/ivacaftor in people living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation
|
Vincken, S.
|
|
|
21 |
S1 |
p. S84
|
artikel
|
| 245 |
P080 Real-world experience of patient outcomes following 1 year of elexacaftor/tezacaftor/ivacaftor treatment at a single adult cystic fibrosis centre
|
Shiner, E.
|
|
|
21 |
S1 |
p. S85
|
artikel
|
| 246 |
P082 Reduced-dose Kaftrio® can significantly improve respiratory health for those intolerant of the recommended dosing schedule
|
Dooney, M.K.
|
|
|
21 |
S1 |
p. S85
|
artikel
|
| 247 |
P058 Resolution of chronic pneumothorax in an adult patient with severe cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor
|
Riberi, L.
|
|
|
21 |
S1 |
p. S77-S78
|
artikel
|
| 248 |
P123 Role of specialised proresolving lipid mediators in the interaction between Aspergillus fumigatus (Af) and cystic fibrosis (CF) bronchial epithelial cells
|
Sy, K.A.
|
|
|
21 |
S1 |
p. S98-S99
|
artikel
|
| 249 |
P072 SARS-CoV-2 infection in patients with cystic fibrosis (CF) - a single centre experience
|
Vidoevska, A.
|
|
|
21 |
S1 |
p. S82
|
artikel
|
| 250 |
P172 Screening for constipation in cystic fibrosis (CF): what are we missing?
|
Still, J.
|
|
|
21 |
S1 |
p. S114
|
artikel
|
| 251 |
P160 “Seeing a trend” - increasing vitamin A levels on elexacaftor/tezacaftor/ivacaftor therapy
|
Proud, D.
|
|
|
21 |
S1 |
p. S110
|
artikel
|
| 252 |
P047 Selection of CFTR modulators for children carrying the genetic variant W1282R
|
Kondratyeva, E.
|
|
|
21 |
S1 |
p. S74
|
artikel
|
| 253 |
P191 Self-compassion explains the positive relationship of mindful eating to uncontrolled and emotional eating in adults with cystic fibrosis
|
Mantzios, M.
|
|
|
21 |
S1 |
p. S120
|
artikel
|
| 254 |
P086 Serum levels of alpha calcitonin gene-related peptide and vasoactive intestinal peptide as predictors of exacerbation in cystic fibrosis
|
Al-Keilani, M.
|
|
|
21 |
S1 |
p. S86
|
artikel
|
| 255 |
P054 Severity of COVID-19 infection in cystic fibrosis patients compared to the general population
|
Rosazza, C.
|
|
|
21 |
S1 |
p. S76
|
artikel
|
| 256 |
P112 Shift of the lung microbiota in patients with cystic fibrosis following antibiotic therapy selected with AtbFinder
|
Tetz, G.
|
|
|
21 |
S1 |
p. S95-S96
|
artikel
|
| 257 |
P043 Significant reduction in abdominal symptoms assessed with the CFAbd-Score over 6 months of elexacaftor/tezacaftor/ivacaftor (ETI) - follow-up results from Irish and British cystic fibrosis patients (RECOVER study)
|
Mainz, J.G.
|
|
|
21 |
S1 |
p. S72-S73
|
artikel
|
| 258 |
P163 Single-centre experience of changes in nutritional parameters in the first 12 months of elexacaftor/tezacaftor/ivacaftor (ETI/Kaftrio®) treatment
|
Snowball, J.
|
|
|
21 |
S1 |
p. S111
|
artikel
|
| 259 |
P207 Spirometric values and 6-minute walking distance in cystic fibrosis patients on elexacaftor/texacaftor/ivacaftor
|
Peruzzi, A.
|
|
|
21 |
S1 |
p. S124
|
artikel
|
| 260 |
P231 Steps Ahead: optimising physical activity in adults with cystic fibrosis - a pilot randomised trial using wearable technology, goal setting and text message feedback
|
Tierney, A.
|
|
|
21 |
S1 |
p. S131
|
artikel
|
| 261 |
P032 Sweat chloride values in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor
|
Cirilli, N.
|
|
|
21 |
S1 |
p. S69
|
artikel
|
| 262 |
P221 Tension-free vaginal tape – a 15-year review of effect on urinary incontinence in patients with cystic fibrosis
|
Kendall, V.
|
|
|
21 |
S1 |
p. S128
|
artikel
|
| 263 |
P149 The association between the cumulative dose of aminoglycoside exposure and hearing loss in children with cystic fibrosis
|
Yegit, C. Yilmaz
|
|
|
21 |
S1 |
p. S106-S107
|
artikel
|
| 264 |
P071 The characterisation of a patient cohort that had home spirometry devices and opted into sharing their data with the US Cystic Fibrosis Foundation
|
Elbert, A.
|
|
|
21 |
S1 |
p. S82
|
artikel
|
| 265 |
P046 The effectiveness of CFTR modulators in people with cystic fibrosis and rare mutations – a real-world study
|
Hanger, S.
|
|
|
21 |
S1 |
p. S73-S74
|
artikel
|
| 266 |
P251 The effect of breathing exercises on the quality of life of 3- to 12-yearold patients with cystic fibrosis and their families
|
Kalyoncu, M.
|
|
|
21 |
S1 |
p. S137-137
|
artikel
|
| 267 |
P042 The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
|
Allgood, S.
|
|
|
21 |
S1 |
p. S72
|
artikel
|
| 268 |
P093 The effect of probiotic administration on glucose metabolism and metabolomics in cystic fibrosis patients
|
Gur, M.
|
|
|
21 |
S1 |
p. S89
|
artikel
|
| 269 |
P181 The effects of linagliptin in patients with a diagnosis of Cystic Fibrosis-Related Diabetes
|
Cunningham, J.
|
|
|
21 |
S1 |
p. S116-S117
|
artikel
|
| 270 |
P239 The experience of virtual visits and home spirometry in caregivers of children with cystic fibrosis
|
Mellqvist, V.
|
|
|
21 |
S1 |
p. S133-S134
|
artikel
|
| 271 |
P244 The experiences of taking Kaftrio® for cystic fibrosis (CF)
|
Mathews, C.
|
|
|
21 |
S1 |
p. S135
|
artikel
|
| 272 |
P212 The impact of Cystic Fibrosis-Related Diabetes on exercise capacity
|
Porter, R.
|
|
|
21 |
S1 |
p. S125
|
artikel
|
| 273 |
P045 The impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on health outcomes in the setting of severe lung disease due to cystic fibrosis
|
Alrehaili, G.
|
|
|
21 |
S1 |
p. S73
|
artikel
|
| 274 |
P055 The impact of virtual care on cystic fibrosis disease progression – a prospective multicentre study in children with cystic fibrosis
|
Medbo, J.
|
|
|
21 |
S1 |
p. S76-S77
|
artikel
|
| 275 |
P229 The introduction of an adherence support clinic in a large UK adult cystic fibrosis centre
|
Choyce, J.
|
|
|
21 |
S1 |
p. S130-S131
|
artikel
|
| 276 |
P067 The main characteristics of cystic fibrosis patients: National Patient Registry of Russia (RCFPR) 2020
|
Kondratyeva, E.
|
|
|
21 |
S1 |
p. S80-S81
|
artikel
|
| 277 |
P213 The 3-minute step test as a predictor of exacerbations in children and adolescents with cystic fibrosis
|
Donadio, M.V. Fagundes
|
|
|
21 |
S1 |
p. S125-S126
|
artikel
|
| 278 |
P166 “The party is over because I nowhave a sensible diet” - the experience of people with cystic fibrosis (CF) on CFTR modulators
|
Collins, S.
|
|
|
21 |
S1 |
p. S112
|
artikel
|
| 279 |
P200 The prevalence of laryngopharyngeal reflux and sino-nasal symptoms in adults with cystic fibrosis
|
Bourke, S.J.
|
|
|
21 |
S1 |
p. S122
|
artikel
|
| 280 |
P026 Theratyping of the CFTR variant G85E in trans with the complex allele A1006E+V562I using rectal organoids
|
Conti, J.
|
|
|
21 |
S1 |
p. S67
|
artikel
|
| 281 |
P193 Thermal sensation and clinical characteristics of patients with cystic fibrosis during extreme heat conditions
|
Anagnostopoulou, P.
|
|
|
21 |
S1 |
p. S120
|
artikel
|
| 282 |
P216 The short-term influence of chest physiotherapy on lung function parameters in children with cystic fibrosis and primary ciliary dyskinesia
|
De Beuckeleer, D.
|
|
|
21 |
S1 |
p. S126-S127
|
artikel
|
| 283 |
P009 The spectrum of CFTR mutations in newly diagnosed cases of cystic fibrosis through newborn screening in the Republic of North Macedonia
|
Fustik, S.
|
|
|
21 |
S1 |
p. S63
|
artikel
|
| 284 |
P098 The use of mucolytic therapy in cystic fibrosis in the Russian Federation
|
Shadrina, V.
|
|
|
21 |
S1 |
p. S90-S91
|
artikel
|
| 285 |
P230 Time matters: the burden of respiratory physiotherapy in adolescents with cystic fibrosis (CF) and their caregivers
|
Blardone, C.
|
|
|
21 |
S1 |
p. S131
|
artikel
|
| 286 |
P222 To assess measured frailty compared to multidisciplinary perception of frailty in the adult cystic fibrosis population
|
Ridgewell, M.
|
|
|
21 |
S1 |
p. S128
|
artikel
|
| 287 |
P096 Tolerability of tigerase (dornase alfa) in children
|
Shadrina, V.
|
|
|
21 |
S1 |
p. S90
|
artikel
|
| 288 |
P255 Transitioning to adult services for children with cystic fibrosis (CF): what matters to all stakeholders?
|
Michael, V.
|
|
|
21 |
S1 |
p. S138
|
artikel
|
| 289 |
P254 Transition to adult care in children with cystic fibrosis – experience over a decade from a large tertiary centre in the northwest United Kingdom
|
Maitra, A.
|
|
|
21 |
S1 |
p. S138
|
artikel
|
| 290 |
P015 Translational readthrough inducing drugs: a study of toxicity in mice models and in vitro safety validation of the specific read-through process
|
Corrao, F.
|
|
|
21 |
S1 |
p. S64-S65
|
artikel
|
| 291 |
P044 Treatment benefits of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying non-F508del mutations
|
Livnat, G.
|
|
|
21 |
S1 |
p. S73
|
artikel
|
| 292 |
P110 Trends in asthma diagnosis and usage of asthma medications in children with cystic fibrosis – are we looking for it?
|
Maitra, A.
|
|
|
21 |
S1 |
p. S95
|
artikel
|
| 293 |
P152 Trends in intravenous antibiotic prescriptions pre- and postintroduction of Kaftrio® in a large UK adult cystic fibrosis centre
|
Choyce, J.
|
|
|
21 |
S1 |
p. S107-S108
|
artikel
|
| 294 |
P106 Upper airway disease in adults with cystic fibrosis: a cross-sectional study
|
Uyttebroek, S.
|
|
|
21 |
S1 |
p. S93
|
artikel
|
| 295 |
P142 Upper and lower airways microbiological status in cystic fibrosis patients in stable conditions and in lung transplant patients
|
Bianchimani, C.
|
|
|
21 |
S1 |
p. S104
|
artikel
|
| 296 |
P228 Using CFHealthHub nebuliser duration data to support continuous improvement by optimising inhaled therapy duration to reduce treatment burden within a digital learning health system
|
Sandler, R.D.
|
|
|
21 |
S1 |
p. S130
|
artikel
|
| 297 |
P017 Using chamber measurement of CFTR modulator effects in airway epithelial cells and its correlation to clinical effects of treatment
|
Aalbers, B.
|
|
|
21 |
S1 |
p. S65
|
artikel
|
| 298 |
P253 Using quality improvement to develop transition to adult care at a UK cystic fibrosis (CF) centre
|
Warnock, L.
|
|
|
21 |
S1 |
p. S137-S138
|
artikel
|
| 299 |
P077 Vaccination of patients with cystic fibrosis during the COVID-19 pandemic in Croatia
|
Markelić, I.
|
|
|
21 |
S1 |
p. S84
|
artikel
|
| 300 |
P089 Ventilation heterogeneity in adult patients with cystic fibrosis (CF)
|
Chernyak, A.
|
|
|
21 |
S1 |
p. S87-S88
|
artikel
|
| 301 |
P088 Ventilation inhomogeneity in patients with cystic fibrosis and pancreatic sufficiency and insufficiency
|
Breuer, O.
|
|
|
21 |
S1 |
p. S87
|
artikel
|
| 302 |
P211 Ventilatory parameters during incremental exercise in patients with cystic fibrosis
|
Alessandro, V.D.
|
|
|
21 |
S1 |
p. S125
|
artikel
|
| 303 |
P188 Vitamin D status at Bristol Adult CF Centre (BACFC) during the COVID-19 pandemic and following the introduction of the multivitamin Paravit CF
|
Keele, A.
|
|
|
21 |
S1 |
p. S119
|
artikel
|
| 304 |
P235 What influence can educational videos have on daily physical therapy in children, adolescents and young adults with cystic fibrosis? A pilot study
|
Cobb, K.
|
|
|
21 |
S1 |
p. S132
|
artikel
|
| 305 |
P158 What is the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on clinical response of cystic fibrosis patients aged ≥ 40 years and their comorbidities?
|
Sapru, K.
|
|
|
21 |
S1 |
p. S109
|
artikel
|
| 306 |
P257 Who’s talking about cystic fibrosis continued: the effects of the COVID-19 pandemic on the cystic fibrosis online landscape
|
Ibrahim, H.
|
|
|
21 |
S1 |
p. S139
|
artikel
|
| 307 |
P003 Wide variability of approach to cystic fibrosis newborn screening across regions of Italy
|
Carducci, C.
|
|
|
21 |
S1 |
p. S62
|
artikel
|
| 308 |
P050 Writing with patients, for patients: co-creation of a cystic fibrosis plain language glossary
|
Hayes, K.
|
|
|
21 |
S1 |
p. S75
|
artikel
|
| 309 |
P242 Young people’s views on Kaftrio®: a peer research project
|
Mindel, E. Lee
|
|
|
21 |
S1 |
p. S134
|
artikel
|
| 310 |
WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK
|
Mainz, J.G.
|
|
|
21 |
S1 |
p. S3
|
artikel
|
| 311 |
WS12.01 Acute pulmonary exacerbations in early cystic fibrosis lung disease are associated with CD3 and PD-1 modulation on lung T cells
|
Giacalone, V.D.
|
|
|
21 |
S1 |
p. S23
|
artikel
|
| 312 |
WS10.06 Adherence to nebulised medication in paediatric patients with cystic fibrosis following introduction of modulator therapy
|
Hu, M.
|
|
|
21 |
S1 |
p. S20-S21
|
artikel
|
| 313 |
WS15.02 A joint model for lung function and nutritional status decline with recurrent pulmonary exacerbations, death, and lung transplantation using cystic fibrosis patient Registry data
|
Afonso, P. Miranda
|
|
|
21 |
S1 |
p. S29
|
artikel
|
| 314 |
WS15.03 A mixed-method systematic review of body image in adults with cystic fibrosis (CF)
|
Sills, D.
|
|
|
21 |
S1 |
p. S29
|
artikel
|
| 315 |
WS01.04 A new weapon against Mycobacterium abscessus
|
Degiacomi, G.
|
|
|
21 |
S1 |
p. S2
|
artikel
|
| 316 |
WS13.01 An invisible threat? Aspergillus-positive cultures and co-infecting bacteria in airway samples
|
Hughes, D.
|
|
|
21 |
S1 |
p. S24-S25
|
artikel
|
| 317 |
WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management
|
VanDevanter, D.R.
|
|
|
21 |
S1 |
p. S1
|
artikel
|
| 318 |
WS18.02 A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation and reduced inflammation in obstructive airway diseases
|
Murabito, A.
|
|
|
21 |
S1 |
p. S35-S36
|
artikel
|
| 319 |
WS21.01 AQP5 and CFTR, two genes associated with pseudo-aquagenic palmoplantar keratoderma?
|
Girodon, E.
|
|
|
21 |
S1 |
p. S41
|
artikel
|
| 320 |
WS09.06 A questionnaire to gain an understanding of adherence to inhaled therapies, airway clearance and exercise since commencing the triple combination modulator in cystic fibrosis
|
Wilson, P.
|
|
|
21 |
S1 |
p. S19
|
artikel
|
| 321 |
WS14.06 A retrospective, longitudinal analysis of pulmonary function and peak oxygen uptake in children and adults with cystic fibrosis
|
Morgan, H.
|
|
|
21 |
S1 |
p. S28
|
artikel
|
| 322 |
WS09.03 A review of patients’ thoughts, feelings and priorities as evidenced in their responses to the paediatric cystic fibrosis annual review questionnaires
|
Watkinson, J.
|
|
|
21 |
S1 |
p. S18
|
artikel
|
| 323 |
WS19.05 Arterialised partial pressure of oxygen: an alternative to FEV1% for tracking cystic fibrosis lung disease in childhood?
|
Gaupmann, R.
|
|
|
21 |
S1 |
p. S38
|
artikel
|
| 324 |
WS15.01 Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis of 3,100 patients
|
Nagy, R.
|
|
|
21 |
S1 |
p. S28-S29
|
artikel
|
| 325 |
WS11.06 A 14-year review of cystic fibrosis newborn screening outcomes from a UK regional laboratory
|
Driscoll, S.
|
|
|
21 |
S1 |
p. S22
|
artikel
|
| 326 |
WS12.02 BAFF and other soluble factors in airway samples are linked with pathological cystic fibrosis neutrophil phenotype in early childhood
|
Schofield, C.J.
|
|
|
21 |
S1 |
p. S23
|
artikel
|
| 327 |
WS16.02 Base editing strategy to repair the CFTR 2789 + 5G > A splicing mutation
|
Amistadi, S.
|
|
|
21 |
S1 |
p. S31
|
artikel
|
| 328 |
WS02.06 Can liver biopsy guide the management of deranged liver function tests in liver transplant recipients receiving Kaftrio?
|
Tachtatzis, P.
|
|
|
21 |
S1 |
p. S5
|
artikel
|
| 329 |
WS17.04 CFTR modulation alters the visco-elastic properties of airway mucus in cystic fibrosis patients
|
Janssens, I.
|
|
|
21 |
S1 |
p. S34
|
artikel
|
| 330 |
WS01.03 CFTR modulators impact antibiotic susceptibility of Pseudomonas aeruginosa and Staphylococcus aureus
|
Cigana, C.
|
|
|
21 |
S1 |
p. S2
|
artikel
|
| 331 |
WS05.02 CFTR rescue by lumacaftor (VX-809) induces an extensive reorganisation of mitochondria in the cystic fibrosis bronchial epithelium
|
Armirotti, A.
|
|
|
21 |
S1 |
p. S9-S10
|
artikel
|
| 332 |
WS12.05 CFTR-TGFβ1 interaction in inflammatory processes in healthy and CFTR-mutated human bronchial epithelial cells
|
Thomassen, J.C.
|
|
|
21 |
S1 |
p. S24
|
artikel
|
| 333 |
WS05.01 Characterisation of the molecular mechanisms underlying PI3Kγ-dependent CFTR stability at the plasma membrane
|
Murabito, A.
|
|
|
21 |
S1 |
p. S9
|
artikel
|
| 334 |
WS04.02 Clinical impact of pathogenic CFTR mutations in paediatric-onset pancreatitis (preliminary analysis from the APPLE study)
|
Juhász, M.F.
|
|
|
21 |
S1 |
p. S7-S8
|
artikel
|
| 335 |
WS11.05 Clinical, microbiological and functional outcomes of children with inconclusive diagnosis of cystic fibrosis following newborn screening (CFSPID/CRMS)
|
Perrin, T.
|
|
|
21 |
S1 |
p. S22
|
artikel
|
| 336 |
WS20.06 Co-infection with Nocardia farcinia and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis
|
Chapman, J.
|
|
|
21 |
S1 |
p. S40-S41
|
artikel
|
| 337 |
WS01.05 Combination of the lytic bacteriophage NP3 with ciprofloxacin has a synergistic effect on biofilms of cystic fibrosis Pseudomonas aeruginosa isolates
|
Ciofu, O.
|
|
|
21 |
S1 |
p. S2-S3
|
artikel
|
| 338 |
WS11.04 Confirmatory genetic testing for all cystic fibrosis screen positive newborns: a 12-year analysis
|
Zhang, S.
|
|
|
21 |
S1 |
p. S22
|
artikel
|
| 339 |
WS08.02 Contemporary incidence of cystic fibrosis in Canada and the United States
|
Stanojevic, S.
|
|
|
21 |
S1 |
p. S15-S16
|
artikel
|
| 340 |
WS16.01 Correction of the drug-refractory CFTR mutation L227R by prime editing
|
Bulcaen, M.
|
|
|
21 |
S1 |
p. S30-S31
|
artikel
|
| 341 |
WS20.05 Cystic fibrosis, lockdown and CFTR modulators - a perfect storm
|
Hufton, M.
|
|
|
21 |
S1 |
p. S40
|
artikel
|
| 342 |
WS21.02 Cystic fibrosis modifier genes and bacterial infections in Spanish patients
|
Granizo-Rodriguez, E.
|
|
|
21 |
S1 |
p. S41
|
artikel
|
| 343 |
WS14.03 Cystic Fibrosis-Related Diabetes is not associated with maximal aerobic exercise capacity in cystic fibrosis (CF): a cross-sectional analysis of an international multicentre trial (ACTIVATE-CF)
|
Radtke, T.
|
|
|
21 |
S1 |
p. S27-S28
|
artikel
|
| 344 |
WS16.06 Development of a high throughput functional screen allows drug repurposing and reveals novel drug candidates for recusing CFTR function in patient-derived organoids with nonsense mutations
|
Spelier, S.
|
|
|
21 |
S1 |
p. S32
|
artikel
|
| 345 |
WS13.06 Development of antibiotic resistance reveals diverse evolutionary pathways to face the complex and dynamic environment of a long-term treated patient
|
Colque, C.A
|
|
|
21 |
S1 |
p. S26
|
artikel
|
| 346 |
WS11.01 Divergent diagnostic assessment of cystic fibrosis and related disorders: an analysis of paediatric cases categorisation by 50 international specialists
|
Albertinetti, S.
|
|
|
21 |
S1 |
p. S21
|
artikel
|
| 347 |
WS04.01 Do adults with Cystic Fibrosis-Related Diabetes on insulin treatment benefit from using flash glucose monitoring?
|
Sunsoa, H.
|
|
|
21 |
S1 |
p. S7
|
artikel
|
| 348 |
WS07.03 Does changing from lumacaftor/ivacaftor (Orkambi) to tezacaftor/ivacaftor + ivacaftor (Symkevi + ivacaftor) offer any clinical benefits in children with cystic fibrosis (CF)?
|
Paskin, L.
|
|
|
21 |
S1 |
p. S13-S14
|
artikel
|
| 349 |
WS03.06 Does the use of modulator therapies in adults with cystic fibrosis have a long-term impact on the requirement for intravenous antibiotics
|
Geoghegan, S.
|
|
|
21 |
S1 |
p. S7
|
artikel
|
| 350 |
WS06.04 Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and 1 or 2 F508del alleles
|
Graeber, S.Y.
|
|
|
21 |
S1 |
p. S12
|
artikel
|
| 351 |
WS07.04 Electronic home monitoring of children with cystic fibrosis to detect and treat acute pulmonary exacerbations and their effect on one year FEV1 loss
|
Yanaz, M.
|
|
|
21 |
S1 |
p. S14
|
artikel
|
| 352 |
WS17.05 Elexacaftor/tezacaftor/ivacaftor (ETI) treatment in people with cystic fibrosis (pwCF) impacts airway progenitor cell function
|
Robinson, N.
|
|
|
21 |
S1 |
p. S34
|
artikel
|
| 353 |
WS20.01 Empowering self-management using intensive support in a patient with challenging Cystic Fibrosis-Related Diabetes and renal failure
|
Snowball, J.
|
|
|
21 |
S1 |
p. S39
|
artikel
|
| 354 |
WS20.04 Enhancing self-compassion and limiting self-criticism in adults with cystic fibrosis decreases the likelihood of hospitalisation
|
Mantzios, M.
|
|
|
21 |
S1 |
p. S40
|
artikel
|
| 355 |
WS18.03 ETD001: a long-acting inhaled ENaC blocker iswell tolerated in humans
|
Russell, P.
|
|
|
21 |
S1 |
p. S36
|
artikel
|
| 356 |
WS10.04 Exploring the effects of Kaftrio on the physiotherapists’ role and service provision for people with cystic fibrosis: a UK and Republic of Ireland (ROI) survey.
|
O’Beirne, O.A.
|
|
|
21 |
S1 |
p. S20
|
artikel
|
| 357 |
WS15.06 Fat-soluble vitamin status in F508del homozygous children with cystic fibrosis following commencement of lumacaftor/ivacaftor
|
Kinsella, A.
|
|
|
21 |
S1 |
p. S30
|
artikel
|
| 358 |
WS18.06 Fully automated analysis of airway-artery dimensions on chest-computed tomography in preschool children with cystic fibrosis to evaluate the effect of inhaled hypertonic saline
|
Chen, Y.
|
|
|
21 |
S1 |
p. S36-S37
|
artikel
|
| 359 |
WS07.06 Geographical distance and survival among adult cystic fibrosis lung transplant recipients in the United States
|
Patel, S.
|
|
|
21 |
S1 |
p. S15
|
artikel
|
| 360 |
WS18.04 Harnessing CRISPR-Cas9 technology to revert F508del-CFTR defect
|
Cereseto, A.
|
|
|
21 |
S1 |
p. S36
|
artikel
|
| 361 |
WS08.03 Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria in People with Cystic Fibrosis (HALT NTM): a multicentre study
|
Gross, J.
|
|
|
21 |
S1 |
p. S16
|
artikel
|
| 362 |
WS06.01 HIT-CF organoid screen with ELX-02 for people with CFTR nonsense mutations as a predictive tool for clinical response
|
Ramalho, A.
|
|
|
21 |
S1 |
p. S11
|
artikel
|
| 363 |
WS12.06 Hypertonic saline triggers inflammatory responses in human macrophages
|
Sposito, F.
|
|
|
21 |
S1 |
p. S24
|
artikel
|
| 364 |
WS16.05 Identification of drugs activating CFTR-independent fluid secretion in nasal organoids based on a high-content screening assay
|
Amatngalim, GD
|
|
|
21 |
S1 |
p. S32
|
artikel
|
| 365 |
WS19.02 Impact of corrected Multiple Breath nitrogenWashout (MBW) software on assessment of under/unventilated lung units (UVLU) with the MBWShX
|
Short, C.
|
|
|
21 |
S1 |
p. S37
|
artikel
|
| 366 |
WS17.06 Impact of elexacaftor/tezacaftor/ivacaftor on lung-recruited neutrophils in cystic fibrosis
|
Cammarata-Mouchtouris, A.
|
|
|
21 |
S1 |
p. S34-S35
|
artikel
|
| 367 |
WS06.02 Impact of one year of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in people with cystic fibrosis in a real-world setting – the RECOVER study
|
McNally, P.
|
|
|
21 |
S1 |
p. S11
|
artikel
|
| 368 |
WS04.04 Impact of planned versus unplanned pregnancy in people with cystic fibrosis
|
Jain, R.
|
|
|
21 |
S1 |
p. S8
|
artikel
|
| 369 |
WS15.05 Impact of refining the U Na/Creat cut-off according to age on the diagnosis of salt depletion in patients with cystic fibrosis
|
Bauraind, O.
|
|
|
21 |
S1 |
p. S30
|
artikel
|
| 370 |
WS03.01 Impact of Trikafta on PHQ-9 and GAD-7 scores
|
Bruschwein, H.
|
|
|
21 |
S1 |
p. S5
|
artikel
|
| 371 |
WS10.01 Impact of triple CFTR modulator therapy on airway clearance and nebuliser adherence in adults with cystic fibrosis
|
Faulkner, J.
|
|
|
21 |
S1 |
p. S19
|
artikel
|
| 372 |
WS10.03 Impact of triple CFTR modulator therapy on urinary incontinence symptoms in adults with cystic fibrosis
|
Faulkner, J.
|
|
|
21 |
S1 |
p. S20
|
artikel
|
| 373 |
WS11.02 Inconsistent IRT threshold values and CFTR panels in newborn screening for cystic fibrosis across the United States
|
Rehani, M.R.
|
|
|
21 |
S1 |
p. S21
|
artikel
|
| 374 |
WS16.04 Inhalation of SP-101 mediates hCFTRΔR transgene expression in the airways of cystic fibrosis and non-cystic fibrosis ferrets
|
Excoffon, K.
|
|
|
21 |
S1 |
p. S31
|
artikel
|
| 375 |
WS17.03 Initiating ivacaftor (IVA) at younger vs older ages improves pulmonary outcomes in people with cystic fibrosis (pwCF): a long-term real-world study
|
Merlo, C.
|
|
|
21 |
S1 |
p. S33-S34
|
artikel
|
| 376 |
WS20.02 Input supporting a young person with increased cough suppression in the context of COVID-19
|
Shayle, A.
|
|
|
21 |
S1 |
p. S39
|
artikel
|
| 377 |
WS08.06 Investigating associations between air pollution and the severity of cystic fibrosis in Great Britain
|
Khan, M. Saleem
|
|
|
21 |
S1 |
p. S17
|
artikel
|
| 378 |
WS02.03 Investigating changes in liver function tests across the first year of elexacaftor/tezacaftor/ivacaftor therapy
|
Robinson, N.J
|
|
|
21 |
S1 |
p. S4
|
artikel
|
| 379 |
WS07.01 Investigating the effects of dornase alfa and hypertonic saline used in combination on lung function in people with cystic fibrosis
|
Granger, E.
|
|
|
21 |
S1 |
p. S13
|
artikel
|
| 380 |
WS07.05 Investigating the relationship between lung function decline and time to death or lung transplantation, accounting for geographical variability
|
Andrinopoulou, E.-R.
|
|
|
21 |
S1 |
p. S14-S15
|
artikel
|
| 381 |
WS13.04 In vivo lung inflammation induced by Achromobacter spp. clinical isolates with different virulence characteristics
|
Sandri, A.
|
|
|
21 |
S1 |
p. S25-S26
|
artikel
|
| 382 |
WS18.05 Linking the compound database CandActCFTR and CFTR lifecycle map to predict possible active compound combinations
|
Vinhoven, L.
|
|
|
21 |
S1 |
p. S36
|
artikel
|
| 383 |
WS02.04 Liver function test abnormalities in cystic fibrosis patients commenced on ELX/TEZ/IVA in a large adult cystic fibrosis centre over 12 months
|
Tewkesbury, D.
|
|
|
21 |
S1 |
p. S4
|
artikel
|
| 384 |
WS17.02 Long-term efficacy of lumacaftor/ivacaftor (LUM/IVA) in children aged 2 through 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F): a phase 2, open-label extension study
|
Stahl, M.
|
|
|
21 |
S1 |
p. S32-S33
|
artikel
|
| 385 |
WS21.03 Low-cost chain termination DNA sequencing PCR reaction to diagnose CFTR gene mutations
|
Ghani, M.U.
|
|
|
21 |
S1 |
p. S41-S42
|
artikel
|
| 386 |
WS07.02 Lumacaftor/ivacaftor in people with cystic fibrosis: factors predisposing the response and impact on lung function decline
|
Mesinele, J.
|
|
|
21 |
S1 |
p. S13
|
artikel
|
| 387 |
WS16.03 LUNAR-CF: an mRNA replacement approach for cystic fibrosis lung disease
|
Geller, D.
|
|
|
21 |
S1 |
p. S31
|
artikel
|
| 388 |
WS19.04 Lung ultrasound in cystic fibrosis bronchiectasis
|
Ciuca, I.
|
|
|
21 |
S1 |
p. S38
|
artikel
|
| 389 |
WS09.01 Make cystic fibrosis research results accessible to all: a French initiative managed by patients and relatives
|
Ruffier, E.
|
|
|
21 |
S1 |
p. S17
|
artikel
|
| 390 |
WS18.01 Manufacturing and device development of SPL84-23-1, an inhaled antisense oligonucleotide, supporting first-in-human clinical study in cystic fibrosis patients carrying the 3849 mutation
|
Hart, G.
|
|
|
21 |
S1 |
p. S35
|
artikel
|
| 391 |
WS13.05 Mapping and tackling diversity in antibiotic resistance of sputum isolates in cystic fibrosis
|
Van den Bossche, S.
|
|
|
21 |
S1 |
p. S26
|
artikel
|
| 392 |
WS05.03 Metabolomic impact of the restoration of CFTR activity in the respiratory epithelium
|
Bardin, E.
|
|
|
21 |
S1 |
p. S10
|
artikel
|
| 393 |
WS21.04 Molecular characterisation of the CFTR gene in the Argentinian population: impact of local variants in the sensitivity of genetic testing
|
Crespo, C.
|
|
|
21 |
S1 |
p. S42
|
artikel
|
| 394 |
WS02.02 MRI metrics of small bowel water in cystic fibrosis (CF) before and after elexacaftor/tezacaftor/ivacaftor: first results from the GIFT-CF3 Study
|
Ng, C.
|
|
|
21 |
S1 |
p. S3-S4
|
artikel
|
| 395 |
WS04.06 Neoplastic disease and treatment in cystic fibrosis (CF): a comprehensive single centre case series
|
Anderson, A.
|
|
|
21 |
S1 |
p. S9
|
artikel
|
| 396 |
WS14.05 Normal fitness data in cystic fibrosis - a scoping review
|
Tomlinson, O.W.
|
|
|
21 |
S1 |
p. S28
|
artikel
|
| 397 |
WS06.03 Novel CFTR modulator combinations maximise functional rescue of G85E and N1303K in rectal organoids
|
Ensinck, M.M.
|
|
|
21 |
S1 |
p. S12
|
artikel
|
| 398 |
WS05.06 Novel high-throughput screening tool for monitoring CFTR levels and localisation in cytoplasm membrane with luminescent peptide tag
|
Ondra, M.
|
|
|
21 |
S1 |
p. S11
|
artikel
|
| 399 |
WS14.01 Outcome measures for airway clearance – better the devil you know? Perspectives from adults with cystic fibrosis (CF)
|
Stanford, G.
|
|
|
21 |
S1 |
p. S26-S27
|
artikel
|
| 400 |
WS08.05 Parenthood impacts short-term health outcomes in people with cystic fibrosis
|
Taylor-Cousar, J.L.
|
|
|
21 |
S1 |
p. S16-S17
|
artikel
|
| 401 |
WS12.03 PD-1 expression on airway macrophages in early cystic fibrosis lung disease coincides with decreased expression of phagocytosis-related markers
|
Slimmen, L.
|
|
|
21 |
S1 |
p. S23
|
artikel
|
| 402 |
WS10.02 People with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy demonstrate improved physical activity levels and cardiovascular fitness
|
FitzMaurice, T.
|
|
|
21 |
S1 |
p. S19-S20
|
artikel
|
| 403 |
WS03.05 Percentage days covered: what does it tell us about adherence to Kaftrio and Kalydeco®?
|
Bevan, A.
|
|
|
21 |
S1 |
p. S6-S7
|
artikel
|
| 404 |
WS10.05 Physical fitness and habitual physical activity in adults with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?
|
Gruber, W.
|
|
|
21 |
S1 |
p. S20
|
artikel
|
| 405 |
WS21.05 Prospective comparison of two sweat test methods
|
Proesmans, M.
|
|
|
21 |
S1 |
p. S42
|
artikel
|
| 406 |
WS19.01 Prospective measurement of lung function in 0–4-year-old Danish children with cystic fibrosis
|
Sandvik, R.M.
|
|
|
21 |
S1 |
p. S37
|
artikel
|
| 407 |
WS05.05 Proximity profiling of the CFTR interaction landscape in response to Orkambi
|
Iazzi, M.
|
|
|
21 |
S1 |
p. S10
|
artikel
|
| 408 |
WS09.04 Psychometric characteristics of the CF Coping Self-Efficacy (CF-CSE) scale
|
Georgiopoulos, A.M.
|
|
|
21 |
S1 |
p. S18
|
artikel
|
| 409 |
WS03.04 Psychosocial outcomes from annual review - a comparison of young people prescribed CFTR medication and those who were not
|
Jones, S.
|
|
|
21 |
S1 |
p. S6
|
artikel
|
| 410 |
WS04.03 Pulmonary impacts of the long-term use of proton pump inhibitors to potentialise the effect of pancreatic extracts in children with cystic fibrosis
|
Awada, S.
|
|
|
21 |
S1 |
p. S8
|
artikel
|
| 411 |
WS03.03 Qualitative analyses of the experiences of people with end-stage cystic fibrosis lung disease receiving ELX/TEZ/IVA
|
Havermans, T.
|
|
|
21 |
S1 |
p. S6
|
artikel
|
| 412 |
WS08.04 Real-world data demonstrate clinical response in people with cystic fibrosis (pwCF) who have select residual function (RF) mutations and are treated with ivacaftor (IVA)
|
Higgins, M.
|
|
|
21 |
S1 |
p. S16
|
artikel
|
| 413 |
WS13.03 Real-world relevancy of qPCR for early detection of Pseudomonas aeruginosa infection in people with cystic fibrosis (pwCF)
|
Héry-Arnaud, G.
|
|
|
21 |
S1 |
p. S25
|
artikel
|
| 414 |
WS11.03 Repeated sweat testing in children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)
|
Postek, M.
|
|
|
21 |
S1 |
p. S21-S22
|
artikel
|
| 415 |
WS19.03 Respiratory impedance analysis at 5 Hz may reveal ventilation inhomogeneity in patients with cystic fibrosis
|
Hatziagorou, E.
|
|
|
21 |
S1 |
p. S37-S38
|
artikel
|
| 416 |
WS05.04 SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells
|
Lotti, V.
|
|
|
21 |
S1 |
p. S10
|
artikel
|
| 417 |
WS09.02 Setting up an e-learning program for male patients presenting cystic fibrosis (CF) infertility
|
Ramel, S.
|
|
|
21 |
S1 |
p. S17
|
artikel
|
| 418 |
WS13.02 Studying the proteome of respiratory samples from cystic fibrosis patients by shotgun proteomics: differences between exacerbation and clinical stability phases
|
Caballero, J.d.D.
|
|
|
21 |
S1 |
p. S25
|
artikel
|
| 419 |
WS21.06 The β-adrenergic sweat secretion test using the AutoBuSTeD software is a novel, high-sensitive CFTR biomarker for patients with inconclusive CFTR genotype and sweat chloride concentration
|
Pallenberg, S.T.
|
|
|
21 |
S1 |
p. S41
|
artikel
|
| 420 |
WS08.01 The changing epidemiology of cystic fibrosis in Europe from 2010 to 2019: data from the European Cystic Fibrosis Society Patient Registry
|
Hatziagorou, E.
|
|
|
21 |
S1 |
p. S15
|
artikel
|
| 421 |
WS06.06 The cystic fibrosis urine bicarbonate challenge test
|
Berg, P.
|
|
|
21 |
S1 |
p. S13
|
artikel
|
| 422 |
WS14.04 The heart of the matter: is cardiac output a limiting factor for maximal exercise capacity in people with cystic fibrosis?
|
Burghard, M.
|
|
|
21 |
S1 |
p. S28
|
artikel
|
| 423 |
WS01.06 The impact of Orkambi on respiratory cystic fibrosis (CF) pathogens
|
Al Shakirchi, M.
|
|
|
21 |
S1 |
p. S3
|
artikel
|
| 424 |
WS17.01 Therapeutic drug monitoring of elexacaftor, tezacaftor and ivacaftor in adult patients with cystic fibrosis
|
Naehrig, S.
|
|
|
21 |
S1 |
p. S32
|
artikel
|
| 425 |
WS02.05 The use of elexacaftor/tezacaftor/ivacaftor in adult patients with cystic fibrosis and established liver cirrhosis: a case series
|
Sun, J.
|
|
|
21 |
S1 |
p. S4-S5
|
artikel
|
| 426 |
WS14.02 Time to first pulmonary exacerbation (PE) in children and adolescents with cystic fibrosis (CF): insights from spirometry, Lung Clearance Index (LCI) and symptoms‐limited exercise test (SLET)
|
Mariani, A.
|
|
|
21 |
S1 |
p. S27
|
artikel
|
| 427 |
WS01.02 Trends and outcomes of long-term inhaled antimicrobial treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection: an ECFSPR data analysis
|
Shteinberg, M.
|
|
|
21 |
S1 |
p. S1-S2
|
artikel
|
| 428 |
WS06.05 Trikafta-mediated bicarbonate transport correction in F508del primary cell cultures
|
Lepissier, A.
|
|
|
21 |
S1 |
p. S12
|
artikel
|
| 429 |
WS15.04 Unanticipated increase in commonly consumed dietary fat when consumed with a new lysophosphatidylcholine-rich nutritional therapy
|
Stallings, V.
|
|
|
21 |
S1 |
p. S29-S30
|
artikel
|
| 430 |
WS03.02 Understanding beliefs about elexacaftor/tezacaftor/ivacaftor (ETI) therapy in adults living with cystic fibrosis
|
O’Leary, C.
|
|
|
21 |
S1 |
p. S5-S6
|
artikel
|
| 431 |
WS12.04 Understanding the mechanism of Staphylococcus aureus killing by neutrophils in the cystic fibrosis airway environment
|
Fantone, K.
|
|
|
21 |
S1 |
p. S24
|
artikel
|
| 432 |
WS09.05 Using the CFHealthHub digital learning health system to optimise the nebulised medicines supply process in 5 UK adult cystic fibrosis (CF) centres
|
Dawson, S.
|
|
|
21 |
S1 |
p. S18-S19
|
artikel
|
| 433 |
WS19.06 Validation of airway-artery algorithm to detect and monitor airway disease on chest computed tomography in the ataluren cystic fibrosis cohort
|
Lv, Q.
|
|
|
21 |
S1 |
p. S38
|
artikel
|
| 434 |
WS04.05 What is the scope for colorectal cancer screening in cystic fibrosis? Ten years of experience at a UK cystic fibrosis centre
|
Sapru, K.
|
|
|
21 |
S1 |
p. S8-S9
|
artikel
|
| 435 |
WS20.03 What to hope for when there is no hope
|
Landau, E.
|
|
|
21 |
S1 |
p. S39-S40
|
artikel
|
Tijdschrift beschrijving